顶部联系方式

Time of issue:2018-03-12 00:00:00

Have Any Questions?  Mabspace BiosciencesInfo@mabspacebio.com 迈博斯生物0512-86861701

搜索
迈博斯生物

语言切换

Time of issue:2019-11-21 00:00:00
这是描述信息

NEWS

>>
>>
Interview with Maibos CEO Qian Xueming: We are doing the world's first pH-dependent PD-L1 antibody

Interview with Maibos CEO Qian Xueming: We are doing the world's first pH-dependent PD-L1 antibody

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2019-11-28 14:39
  • Views:

(Summary description)Dr. Qian Xueming, who has worked for multinational pharmaceutical giant Amgen for more than 12 years, finally embarked on a journey home. After more than two years of preparation, he founded his own b

Interview with Maibos CEO Qian Xueming: We are doing the world's first pH-dependent PD-L1 antibody

(Summary description)Dr. Qian Xueming, who has worked for multinational pharmaceutical giant Amgen for more than 12 years, finally embarked on a journey home. After more than two years of preparation, he founded his own b

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2019-11-28 14:39
  • Views:
Information

Dr. Qian Xueming, who has worked for multinational pharmaceutical giant Amgen for more than 12 years, finally embarked on a journey home. After more than two years of preparation, he founded his own biopharmaceutical company, Maibos Bio. With the self-developed new antibody discovery technology, the company has the world's first pH-dependent binding PD-L1 antibody. Recently, in an interview with BioExploration, Qian Xueming revealed: "At present, this antibody has been clinically declared in China and is being reported to the US FDA for IND. It is expected to conduct clinical trials in the United States in the first quarter of 2018."

 

Dr. Xueming Qian, Founder and CEO of Maibos

 

1 Amgen 12 years, planting the seeds of entrepreneurship

 

As the "first stop" of his career, Qian Xueming served at Amgen for twelve and a half years. In 1997, Qian Xueming joined Amgen's Molecular Genetics Department as a post-doctoral research and development of new bioengineering drugs; 3 years later, he successfully promoted to a scientist and participated in and led multiple R & D projects for antibodies and small molecules; in 2005, Rong Sheng As the chief scientist, and in the following five years, he led the team to develop the first antibody candidate for the treatment of chronic renal failure in the world.

 

"A company like Amgen is a very good 'university'." Qian Xueming said of his "old owner". At the 64th event of Tongxieyi Forum, he told BioExplorer that leading a new drug research and development project in such a large company is actually like running a small company. This is a very big challenge, but it is also the most valuable experience.

 

In 2010, Qian Xueming returned to China. The reason why he made such a choice is closely related to the "entrepreneurial dream" in his mind. However, the first step after his return was not to start his own company immediately, but to leave himself a period of preparation. During this period, he learned about the domestic medical environment, the government's operating model, and the "wind direction" of venture capital. The most important thing is to define his own company's positioning-a biotechnology that can compete with other companies on the international stage the company.

 

In October 2012, Maibosi Biopharmaceutical (Suzhou) Co., Ltd., which bears the "dream of first-class new drug development", was incorporated. During the interview, Qian Xueming told Biology Exploration that he is a Suzhou native. The reason why he chose to start a business in Suzhou is because the city revealed a “just right” temperament in terms of entrepreneurial environment, infrastructure, and consumption . It's easier to balance work and life here.

 

2Breakthrough limitations, new antibody discovery technology finds "world's first"

 

In the first half of the year after the company was founded, Qian Xueming and his team have been focusing on developing a new antibody discovery technology, namely, Immune Tolerance Breaking Technology (IMBT). "In simple terms, IMBT technology enables the use of mice to screen the best antibodies against human proteins in a larger epitope space," he explained.

 

At present, this technology has become the core competitiveness of Maibosi, helping the company to screen the world's first and only pH-dependent binding PD-L1 antibody. What kind of performance advantage does this antibody represent behind this "world's first" title? During the interview, Qian Xueming used two recording pens and a mobile phone to vividly answer this doubt to biological exploration.

 

He said: "If a complete tumor is simply divided into the outer layer, the middle layer and the inner layer, then it is clear that the drug concentration in the outer layer is the highest, and the further the inner layer, the lower the drug concentration. Because of the antibody Drug affinity is very high, and it is very difficult to transfer drugs between tumor layers. Therefore, many drugs are left in the outer layer and then gradually degraded by endocytosis. In this case, only the blood and outer layer The drug concentration has been kept at a very high level in order to have enough drugs to reach the middle and inner layers of the tumor and kill cancer cells in these areas. This is why the dosage of PD-L1 antibody approved for marketing is very high. "

 

"Obviously, it is one of the ways to improve the anti-cancer effect by making the outer layer of drugs better delivered to the middle and inner layers, so that all parts of the tumor can be exposed to the concentration of the drug that has the ability to effectively kill cancer cells. This is what our world's first pH-dependent binding PD-L1 antibody can do. This feature makes the dosage of this PD-L1 antibody much lower than the products already on the market, and the effect is better at the same dose, and at the same time Reduces the impact of the drug on healthy tissue, mentioning safety and tolerance. "

 

3Although it started late, it strives to be the best PD-L1 antibody

 

PD-1 / PD-L1 antibody, as a new type of anti-cancer therapy that has risen in recent years, is considered by many to be another subversive development in the history of cancer treatment. The US FDA has approved the listing of five PD-1 / PD-L1 antibodies, three of which are PD-L1 antibodies, namely Tecentriq from Roche, Bavencio from Merck / Pfizer, and Imfinzi from AstraZeneca.

 

Data from preclinical studies show that compared with PD-L1 antibodies from Roche and AstraZeneca, Maibos' pH-dependent binding to PD-L1 antibodies has a more obvious tumor suppressive effect, and it does not require high doses to show, and Sustained suppression for longer. At present, this PD-L1 antibody has been reported clinically in China, and is currently applying for IND to the US FDA, and it is expected to conduct clinical trials in the United States in the first quarter of next year. Qian Xueming said: "If your product is later than others, then you must find your own" selling point. "

 

The market value of PD-1 / PD-L1 antibodies is beyond doubt. When asked about the company's future market prospects for PD-L1 antibodies, Qian Xueming said: "Although there are currently 5 PD-1 / PD-L1 antibodies approved for listing, many large and small pharmaceutical companies around the world are still active The development of such drugs is promoted because PD-1 / PD-L1 antibodies have very wide indications and can treat many types of cancers. As far as the Chinese market is concerned, there may be 7-8 PD-1 / The PD-L1 antibody is approved for listing and the market size will reach 10 billion. If Maibos can get a 5% -10% market share, it will already be a very good return. "

 

During the interview, Qian Xueming also revealed to Bio-Exploration that in the past two years, many domestic companies have chosen to cooperate with international pharmaceutical giants to develop independently developed PD-1 / PD-L1 antibodies. In the future, Maibos will not rule out “going this road". He said: "Working with large pharmaceutical companies, they can provide not only financial support, but their extensive experience in all aspects of drug development will greatly increase the likelihood of successful new drug development. On the other hand, a small It is very difficult for a company to cover its 'footsteps' around the world on its own. Cooperation with large pharmaceutical companies is an important way to help the company go global. "

 

He also emphasized: "All our final decisions will be to be able to maximize the potential value of a drug. Therefore, whether it is developed independently or in cooperation with other companies, as long as the drug can be marketed, it will be a great success . "

 

4 make innovative drugs, not just focus on cancer

 

During the interview, BioExplorer also learned that, in addition to focusing on the highly competitive cancer field, Maibos, which is committed to the development of innovative antibody drugs, is also actively developing "non-hot" antibodies for fibrotic disorders. drug.

 

Tissue fibrosis plays an important role in the occurrence and development of diseases of the main organs of the human body, and is the main cause of disability and death of many diseases. These diseases include cardiovascular disease, respiratory disease, liver disease, kidney disease, cancer, and various immune system diseases. Earlier data showed that nearly 45% of deaths in the United States due to various diseases can be attributed to tissue fibrosis.

 

Qian Xueming told BioExploration: "With the help of IMBT technology, we have screened leading antibodies against these diseases. At present, there are only a few small molecule drugs on the market for treating fibrotic diseases. If we can develop a change in the current treatment status This is definitely an important innovation. "

 

At the end of the interview, he pointed out that the ability to continuously innovate is crucial to the development of a company. In addition to the existing IMBT technology, the company also introduced a number of experienced personnel related to all aspects of antibody drug development. In addition, the company is currently in the B round of financing. The triple guarantee of technology, talents and funds will help the company stand out in the "shuffle" of the Chinese antibody industry in the next 5-10 years.

Scan the QR code to read on your phone

页脚关于我们

Time of issue:2019-11-23 00:00:00

页脚管道

Time of issue:2019-11-23 00:00:00

页脚新闻

Time of issue:2019-11-23 00:00:00

页脚人力资源

Time of issue:2019-11-23 00:00:00

页脚联系方式

Time of issue:2019-11-23 00:00:00

页脚版权

Time of issue:2019-11-23 00:00:00

Copyright © 2019 Mabspace Biosciences All rights reserved

页脚备案

Time of issue:2019-11-23 00:00:00